Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|December 1, 2002
Oncology NEWS International
- Oncology NEWS International Vol 11 No 12
- Volume 11
- Issue 12
Feds Fund CAM Use Study
WASHINGTON-A 2-year, $1 million study by the Institute of Medicine (IOM) will explore the scientific and policy implications of complementary and alternative medicine (CAM). The study is being funded by 16 units of the National Institutes of Health, including the National Cancer Institute, and the Agency for Healthcare Research and Quality. The IOM, a part of the National Academy of Sciences, will name a committee of about 16 experts to carry out the study. Panel members will be chosen from among leading CAM specialists and more conventional disciplines.
Advertisement
WASHINGTONA 2-year, $1 million study by the Institute of Medicine (IOM) will explore the scientific and policy implications of complementary and alternative medicine (CAM). The study is being funded by 16 units of the National Institutes of Health, including the National Cancer Institute, and the Agency for Healthcare Research and Quality. The IOM, a part of the National Academy of Sciences, will name a committee of about 16 experts to carry out the study. Panel members will be chosen from among leading CAM specialists and more conventional disciplines.
Articles in this issue
almost 24 years ago
Stereotactic Radiosurgery Benefits Brain Met Patientsalmost 24 years ago
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Reportalmost 24 years ago
Tailored Messages Motivate Women to Get Mammogramsalmost 24 years ago
Chemo/Rituximab Is Effective as First-Line CLL Therapyalmost 24 years ago
Preoperative Capecitabine/RT Downstages Rectal Canceralmost 24 years ago
Intraoperative Lymphatic Mapping Enhances Cancer Stagingalmost 24 years ago
Rituximab Ups Survival in Aggressive and Indolent NHLalmost 24 years ago
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trialalmost 24 years ago
Lower Breast Cancer Survival in Hispanics: New Mexico StudyAdvertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5